(AOF) – OSE Immunotherapeutics announces the presentation of the first phase 1 clinical results of BI 770371, a new anti-SIRPα monoclonal antibody evaluated in solid tumors, at the ESMO (European Society for Medical Oncology) conference which is being held in Madrid, Spain until tomorrow October 24. “We congratulate our partner Boehringer Ingelheim for this significant new progress, achieved within the framework of our global collaboration and licensing agreement, which demonstrates its commitment,” announces Managing Director Nicolas Poirier.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
